Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

January 2024

Continued JAK Inhibitor Treatment on the Risk of Recurrent Herpes Zoster Reactivation in Patients with Immune-mediated Inflammatory Diseases: A Nationwide Population-based Study in South Korea

Semin Arthritis Rheum 2024 doi 10.1016/j.semarthrit.2024.152362 Epub ahead of print

Kim YE,

Kim YJ,

Jeong DH,

Kim S,

Kim MJ,

Kim HH,

Jo KW,

Park SH,

Hong S

This real-world study by Kim, et al. found no significant relationship between continued JAK inhibitor therapy in patients with IMIDs and the risk of subsequent recurrent HZ reactivation. They also found no significant difference in the number of days patients were treated for HZ in the JAK inhibitor continuation and discontinuation groups.

Keywords:

February 2023

Eficácia Clínica dos Inibidores Alternativos de TNF e Secukinumabe entre Não-Respondedores Primários e Secundários a uma Terapia Prévia com Inibidor de TNF em Espondilite Anquilosante

Mod Rheumatol. 2023 doi: 10.1093/mr/roac005

Min HK,

Kim HR,

Lee SH,

Hong YS,

Kim MY,

Park SH,

Kang KY

This study demonstrated comparable drug retention between AS patients treated with alternative TNFi and secukinumab after failing to respond to prior TNFi therapy. The objective of this study was to compare the drug retention times and clinical efficacy of alternative TNFi and secukinumab in primary and secondary
non-responders with AS.